Ubs Asset Management Americas Inc Cytek Biosciences, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 284,350 shares of CTKB stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
284,350
Previous 191,624
48.39%
Holding current value
$1.13 Million
Previous $768,000
25.78%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CTKB
# of Institutions
156Shares Held
73.9MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$67.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.77MShares$30.8 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD7.11MShares$28.2 Million0.72% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$26.4 Million0.93% of portfolio
-
State Street Corp Boston, MA4.17MShares$16.6 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $534M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...